Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge
06 avr. 2022 12h14 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that a team of three company scientists were named one of the winners of the Pediatric...
Vir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference
04 avr. 2022 16h02 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the 21st Annual Needham Healthcare...
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant
25 mars 2022 16h04 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, March 25, 2022 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the US Food and Drug Administration has amended...
Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference
02 mars 2022 16h02 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, March 02, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in an infectious disease panel discussion at the 42nd Annual...
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
24 févr. 2022 16h04 HE
|
Vir Biotechnology, Inc.
– Significant progress made increasing global patient access to sotrovimab; approximately 1.7 million doses sold to date – – $917.2 million of sotrovimab collaboration revenue recognized in 2021 – –...
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
10 févr. 2022 16h02 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter...
Data Suggest Sotrovimab Retains Neutralizing Activity Against Omicron Subvariant BA.2
10 févr. 2022 01h24 HE
|
Vir Biotechnology, Inc.
– Pseudovirus results being shared with government and regulatory authorities;publication in bioRxiv anticipated in the coming week; additional live virus testing underway – SAN FRANCISCO, Feb. 09,...
Vir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global
08 févr. 2022 06h00 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Johanna Friedl-Naderer as Executive Vice President and Chief...
Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure for HIV and Prevention of Malaria
13 janv. 2022 09h05 HE
|
Vir Biotechnology, Inc.
– New commitment from the Bill & Melinda Gates Foundation supports the development of Vir’s novel “vaccinal antibody” technology as another important step in the fight to address global...
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
13 janv. 2022 09h02 HE
|
Vir Biotechnology, Inc.
– If authorized, would provide the option for intramuscular administration of sotrovimab, in addition to currently authorized intravenous administration – – Submission follows COMET-TAIL Phase 3...